Overall , the current meta- analysis demonstrated that ALA administration may lead to an improvement in glucose homeostasis parameters and lipid profiles except HDL-cholesterol levels
OBJECTIVE This systematic review and meta- analysis of r and omized controlled trials ( RCTs ) was performed to summarize the effect of alpha-lipoic acid ( ALA ) supplementation on glycemic control and lipid profiles among patients with metabolic diseases .
Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant α-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus.
BACKGROUND Short-term continuous subcutaneous insulin infusion ( CSII ) in patients with newly diagnosed type 2 diabetes has been proved effective in improving metabolic control and β-cell function , thus inducing long-term drug-free remission . A r and omized controlled trial was conducted to investigate whether CSII in combination with rosiglitazone , metformin , or α-lipoic acid separately brings about extra benefits . PATIENTS AND METHODS One hundred sixty patients with newly diagnosed type 2 diabetes were r and omized to one of four treatment groups : CSII alone , CSII in combination with rosiglitazone or metformin for 3 months , or CSII with α-lipoic acid intravenous infusion for 2 weeks . Duration of CSII treatment was identical in the four groups . Glucose and lipid profiles , homeostasis model assessment ( HOMA ) indices , acute insulin response ( AIR ) , intramyocellular lipid ( IMCL ) level , and malondialdehyde level were compared before and after intervention . RESULTS The near-normoglycemia rate at the third month in CSII alone and that in combination with rosiglitazone , metformin , or α-lipoic acid was 72.5 % , 87.5 % , 90 % , and 75 % , respectively ( metformin group vs. CSII alone , P=0.045 ) . The metformin group achieved euglycemia in a shorter time ( 2.6 ± 1.3 vs. 3.7 ± 1.8 days , P=0.020 ) with less daily insulin dosage and was more powerful in lowering total cholesterol , increasing AIR and HOMA β-cell function , whereas reduction of IMCL in the soleus was more obvious in the rosiglitazone group but not in the metformin group . The efficacy of combination with α-lipoic acid was similar to that of CSII alone . CONCLUSIONS Short-term CSII in combination with rosiglitazone or metformin is superior to CSII alone , yet the efficacy of the two differs in some way , whereas that with α-lipoic acid might not have an additive effect
Overall , the current meta- analysis demonstrated that ALA administration may lead to an improvement in glucose homeostasis parameters and lipid profiles except HDL-cholesterol levels
OBJECTIVE This systematic review and meta- analysis of r and omized controlled trials ( RCTs ) was performed to summarize the effect of alpha-lipoic acid ( ALA ) supplementation on glycemic control and lipid profiles among patients with metabolic diseases .